Compare Cassava Sciences Inc (FLNA) vs Lam Research Corporation (LRCX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Lam Research Corporation — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Lam Research Corporation trades at $327.78 (market cap $419.48B). The key difference: Lam Research Corporation is far larger — about 7893.9× Cassava Sciences Inc's market cap, and Lam Research Corporation pays a 0.31% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | LRCX | |
|---|---|---|
Market Cap | $53.14M | $419.48B |
Sector | Health | Technology |
52-Week High | $4.64 | $433.33 |
52-Week Low | $1.09 | $94.84 |
Enterprise Value | -$33.43M | $418.46B |
Dividend Yield | — | 0.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
Lam Research (LRCX) trades at $346.10, up 4.9% in the last session, reflecting strong momentum in semiconductor equipment stocks. The stock exhibits bullish technical signals with support at $340 and resistance at $350. Fundamentally, the company reported revenue of $18.44B and net income of $5.36B in 2025, with a robust net margin of 30.94%. Recent quarterly earnings consistently beat expectations, and analyst consensus remains overwhelmingly positive with a $393 price target. The company benefits from AI-driven demand for advanced chip fabrication equipment.
The outlook for LRCX is positive, driven by secular growth in AI and high-performance computing, which fuels demand for its wafer fabrication equipment. Investment opportunities include continued market share gains and margin expansion. Key risks include cyclical semiconductor capital expenditure downturns, intense competition from peers like Applied Materials, and a premium valuation (P/E of 63.41) that leaves the stock vulnerable to multiple compression if growth expectations moderate.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Lam Research Corporation
Lam Research manufactures equipment used to fabricate semiconductors. The firm is focused on the etching, deposition, and clean markets, which are key steps in the semiconductor manufacturing process, especially for 3D NAND flash storage, advanced DRAM, and leading-edge logic/foundry chipmakers. Lam's flagship Kiyo, Vector, and Sabre products are sold in all major geographies to key customers such as Samsung Electronics, Micron, Intel, and Taiwan Semiconductor Manufacturing.
Read more on LRCX →
